Vir Biotechnology

IPO

Powering the Immune System to Transform Lives

Public · San Francisco, United States · Founded 2016 · $250.0M raised

Employees
201–500
Founded
2016
Business Model
B2B
Website
vir.bio
Total Funding
$250.0M
Last Round
$250.0M Growth EquityOct 2024
Rounds
2
Type
Public

About

Vir Biotechnology is a clinical-stage immunology company leveraging the immune system to develop treatments for infectious diseases and cancer. Its pipeline is built on two core platforms: a next-generation antibody platform and the PRO-XTEN protease-releasable masking technology. Lead programs target chronic hepatitis delta, oncology, HIV, and other serious conditions with high unmet need.

Summary

Vir Biotechnology is a Biotech company based in San Francisco, United States, founded in 2016. It has raised $250.0M in total across 2 rounds, most recently a $250.0M Growth Equity round in Oct 2024. Investors include GV and ARCH Venture Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondaryFeb 2026

Sign up to see all 3 rounds

Venture Round through Secondary Market — per-round amounts, valuations, and who invested in each round.

Investors

Acquisitions

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Vir Biotechnology on Indexed.vc
<a href="https://indexed.vc/companies/vir-biotechnology"><img src="https://indexed.vc/api/badge/company/vir-biotechnology" alt="Vir Biotechnology on Indexed.vc" width="260" height="76" /></a>